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The current outbreak of Ebola virus disease (EVD) in
West Africa involves members of the Royal College of
Physicians of Edinburgh supporting the response on the
ground, particularly in Sierra Leone, and I offer these
thoughts as a clinician who had been transplanted into
the outbreak at various times and locations from
overseas.Those most experienced in the management of
the outbreak are those residents of affected countries
who continue to work to prevent, respond and contain
the outbreak in the long term, with little resource and
less recognition.
Time moves quickly in outbreaks but understanding
develops more slowly. For decades since the first EVD
outbreak in Africa in 1976, our predecessors learnt about
the pathogen and its consequences in brief periods of
time and with limited numbers of patients.The perspective
has been from the vantage of those critically ill, late
presenting patients from remote communities, detected
because of the severe course of their illness.
No reader will be surprised at the idea that this EVD
outbreak in West Africa is different.1 It is large. It is diverse.
It has had time to develop its character. Some feel that this
character is a marked departure from our previous
understanding of EVD outbreaks; and that the pathogen
continues to evolve, possibly with clinical consequences.
We have accumulated sufficient experience with enough
patients and places to get a better sense of the disease.
We also have a larger pool of clinicians with direct
experience.Those few forebears in the field from previous
outbreaks may not be surprised at all.
Clinically, before this outbreak, the common perception
was that EVD patients bleed then die. Sometimes they
do. Like the vast majority of known diseases, patients
present across a spectrum of severity.The historical case
fatality rate (CFR) of 9 out of 10 patients has regressed
to a new mean, although we are not sure yet what that
mean is. A publication by the World Health Organization
(WHO) reviewing the first 9 months of the current
outbreak asserted that West Africa experienced a CFR

of nearly 71%.2 However, patients who present to care,
especially early to care, are likely to fare better. Effective
care centres in the right circumstances have achieved a
CFR of less than 50% in affected areas. Referral centres
outside of Africa have achieved very low CFRs with small
numbers of patients.
Clinicians have come to appreciate more broadly that
care of EVD patients can be both safe and effective.3
Many good infection prevention and control practices
lead to more efficient, focused time in the isolation area
directly tending to patients. Safe and effective care is
practicable and important in resource limited as well as
advanced care settings. Published reports of the details
of presentation and care exist for some of the affected
countries and exported cases.4-7
Clinical care is a core part of the overall outbreak response,
not an activity apart. Early case identification, care of the
patient and robust contact tracing and monitoring are
inextricably linked and essential in the interruption of
chains of transmission as well as part of the foundation of
community/response team relationships. While broad
community empowerment and behavioural change
strategies are important in any outbreak setting, early
containment of an outbreak requires a comprehensive
clinical management strategy. This strategy must
recognise the importance of safely achieving good
clinical outcomes in EVD patients while reinforcing
other elements of the response.
Broader clinical perspectives have been published.3 Several
of the WHO clinical consultants in this outbreak have
constructed key points around executing safe and effective
care for suspected and confirmed EVD patients.8 There
are book chapters on EVD.9 As to clinical preparedness,
there are no substitutes for keeping up-to-date with
relevant guidelines and recommendations.1,10,11
As a physician, I cannot help but focus on my own clinical
experience. While I participated in patient care in varied
places and times in the outbreak, such lessons are
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inherently biased. Each responding clinician experiences a
different outbreak, as patients and communities are unique.
A two to four day non-distinct febrile prodrome was
common. Occasionally a patient would present without
fever but with other symptoms. This was rare and fever
almost always developed soon after presentation. Malaria
infection on presentation or subsequently during the
hospital course also was common, diagnosed clinically or
with specific DEFINE rapid assays. Patients with malaria
and EVD seemed to have more challenging clinical
courses. Distinct EVD clinical syndromes have been useful
in approaching patients in my care, though the syndromes
are not easily represented by the way that signs and
symptoms typically are recorded in the outbreak.
Febrile arthralgia was demonstrated at presentation by a
small group of patients with low mortality, 1:5–10 when
admission registries were available for review. In overt
clinical appearance these patients appeared similar to
those with mild to moderate dengue fever. Adverse
outcomes in this group were unusual, though occasionally
a stroke or other isolated event occurred, particularly in
those patients who were older and had comorbidities.
Sometimes patients in this group would develop limited
gastrointestinal symptoms. I have been suspicious that
these patients were demonstrating a sero-conversion
arthropathy. In some ways they reminded me of children
with post-meningococcal arthritis. Patients who
presented initially with febrile enteropathy sometimes
develop this clinical picture during recovery.
Diarrhoea with or without vomiting was the dominant
symptom in the febrile enteropathy group. Sometimes
vomiting persisted but in other instances it was limited
and sporadic. Fluid losses were high. Some patients,
particularly those who had been symptomatic for a few
days prior to presentation, had a 10 litre or greater
water deficit and persistent 4–6 litre daily resuscitative
requirements. Patient recognition of the importance of
replenishing volume in the setting of diarrhoea at home
was unusual. Sometimes I could rely upon oral rehydration
solution intake, particularly when patients coached each
other using intake targets. However, parenteral volume
and empiric electrolyte repletion was often needed.
Most patients improved or declined within a week of
admission, but the clinical course could vary for up to
three weeks and still result in survival. Variable non-focal
abdominal pain, sometimes cramping and migratory with
bloating similar to giardiasis, at other times briefly focal
with rebound that soon afterwards was absent, was
common.There seemed to be a slight epigastric and right
upper quadrant preponderance to the discomfort.
Transient improvements of less than two days would
occur, but full improvement for more than two days was
not followed by recurrence of symptoms. In some
instances, limited point-of-care chemistry information on
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patients was available. Profound metabolic acidosis was
common, sometimes also with an overlying hyperchloremic
metabolic acidosis depending on the resuscitative fluid
availability. Hypokalaemia was common and sometimes
profound. Many patients had a hepatocellular dominant
hepatitis with transaminases of several hundred
U/L. Amylase, lipase and coagulation studies were not
available to me though others have reported that
pancreatic enzyme elevations were also common.
Cytologic analysis was not reliable in my settings.
Moderate to severely ill patients often developed a deep
central chest discomfort and anxiety that persisted and
was difficult to manage either because of a lack of more
potent analgesia or inability to visit frequently enough to
administer short acting formulations. Thrush was
common. A wide range of mental status changes were
apparent in this group. Hiccups often seemed to be
associated with declining volume status or worsening
acidosis and would resolve with volume repletion over
hours to days, returning when there was a drop in fluid
replacement. It was a clinical warning that triggered
escalations in fluid replacement similar to increasing
compensatory tachypnea from metabolic acidosis. This is
in contradistinction to others’ experience in previous
outbreaks where hiccups had been perceived to be a
pre-terminal sign. Some patients had non-pitting oedema
during resuscitation but had persistent intravascular
volume deficits that were apparent through measuring
orthostatic pulse and blood pressure.
Bleeding in general was a late sign and then potentially
profound; not, however, mild to moderate mucosal
bleeding (oropharyngeal, melaena, haematochezia)
sometimes occurred early during presentation and then
resolved in recovering patients.
Most references discuss a rash but, in my experience, the
rash was variably present. It was a fine, mostly central
papular rash that was sometimes pruritic. Patients rarely
mentioned the rash without prompting. I usually noted it
while palpating and not on casual inspection. The rash
reminded me of presentations of secondary syphilis and
vasculitis. A test for syphilis on Ebola infected blood was
not available to me.
Oxygen requirements were rare. When oxygen
requirements were present, the patient appeared to have
a pulmonary embolus or pneumonia. Tachypnoea was
common. In patients without an apparent or likely
pulmonary event, they had no insight into their respiratory
effort. The tachypnoea appeared compensatory for the
patients’ metabolic acidosis.
Confusion, behavioral disturbance and the ‘starry-eyed
stare’ were common findings among moderately and
severely ill patients. Metabolic derangement either from
electrolyte loss, renal or hepatic injury, viral effects,
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Increasing experience with patients in referral critical care
units has been gained in a wide range of centres, including
at the Royal Free Hospital in London as well as in Germany,
Italy, Spain, France and across the United States. Patient
presentation and care in these settings has distinct features
in contrast to field settings where the patients are from the
local community and full volume repletion and advanced
interventions are unlikely. Lung injury and other
consequences of later stage disease as well as volume
overload were sometimes observed in the course of
aggressive, successful care.
Managing these patients in any setting is like managing any
patient with severe sepsis or shock, using targeted
strategies appropriate to the patient’s needs and the level
of resources available. The broad, direct effects of the
virus, volume and electrolytes status, the presence of
concomitant or supervening infections, organ injury,
delirium, co-morbidities including nutritional status,
palliation of sometimes profound pain and anxiety and
basic elements of patient safety when hospitalised or
isolated all require attention. Robust infection prevention
and control practice must be integral to how this is done.

Looking ahead, the biodefence industry has brought
several diagnostic, preventive and therapeutic products
in use or near the point of beginning clinical assessment.
WHO facilitates and reports on these through its New
Interventions initiative.1 The most critical intervention is
the introduction of clinical practice which we all would
expect at our own centres. Should EVD therapeutics be
validated and more available, they may be useful for a
range of patient-centred outcomes. Decreasing mortality
is important as is the reduction of time spent in isolation,
making patients feel better, preventing disease in close
contacts of confirmed cases, deconstructing the barriers
to receiving critical non-EVD care and re-launching
broad public programming around managing maternal
haemorrhage, childhood respiratory and enteric disease
reduction and treatment, malaria, HIV, TB and many
others. Improvements in the management of pregnant
EVD patients, very young children and those with
neuropredominant syndromes would be welcome.
The gains in this outbreak have been slow, hard won and
sometimes transient. Hopefully, we will see those gains
include more baseline capacity that endures and increased
preparedness for the next special pathogens outbreak.
Disclaimer
The views expressed in this article are those of the
author and do not necessarily reflect the official policy
or position of the Uniformed Services University of the
Health Sciences, Department of the Navy, Department
of Defense, nor the US Government.
DMB is a military service member. This work was
prepared as part of his official duties.Title 17 USC section
105 provides that ‘Copyright protection under this article
is not available for any work of the US Government.’ Title
17 USC section 101 defines a US Government work as a
work prepared by a military service member of the US
Government as part of that person’s official duties.
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consequences of uncontrolled pain, adrenal insufficiency
and acute nutritional deficits all seemed possible in
various patients. Seizures occurred but were uncommon. In
some patients, who appeared at risk for vasculopathy
(obesity especially with adult-onset diabetes and older age),
cognitive deficits were more marked. Occasionally, paratonia,
perseveration and frank delirium were apparent. This last
group of patients was particularly difficult to manage and
seemed to have a higher incidence of what could have been
cerebrovascular events with stepwise deterioration,
although severe metabolic disturbances could not be
excluded in some settings. Mortality was high. While
gastrointestinal signs and symptoms were present in this
group, the neurocognitive features were more persistent.

